These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 7332939)

  • 1. [Risks in the delivery of drugs from the point of manufacture to the patient. I. Risks in manufacturing and compounding].
    Samková M; Solich J
    Cesk Farm; 1981 Dec; 30(10):349-54. PubMed ID: 7332939
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of compounding on sterility and stability of drugs.
    Hardee GE
    J Am Vet Med Assoc; 1994 Jul; 205(2):224-5. PubMed ID: 7928582
    [No Abstract]   [Full Text] [Related]  

  • 3. Anticipated revisions to the current good manufacturing practice regulations.
    Mitchell CM
    Bull Parenter Drug Assoc; 1974; 28(3):146-51. PubMed ID: 4845938
    [No Abstract]   [Full Text] [Related]  

  • 4. Cleaner medicaments.
    Br Med J; 1973 Apr; 2(5857):6. PubMed ID: 4695717
    [No Abstract]   [Full Text] [Related]  

  • 5. [The microbiological faultlessness of drugs. III. Development and problems of testing methods].
    Sagáth J; Chalabala M; Bábik I
    Cesk Farm; 1978 Oct; 27(8):353-8. PubMed ID: 743754
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug diversion and counterfeiting.
    Veiga RV; Aronson J
    Am Fam Physician; 1989 Oct; 40(4):81, 84. PubMed ID: 2801471
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug identification. The problem in dental out-patients.
    Stephen KW; Laird WR
    Br Dent J; 1968 Jun; 124(11):521-5. PubMed ID: 5239909
    [No Abstract]   [Full Text] [Related]  

  • 8. WHO expert committee on specifications for pharmaceutical preparations. Twenty-fifth report.
    World Health Organ Tech Rep Ser; 1975; (567):1-115. PubMed ID: 807046
    [No Abstract]   [Full Text] [Related]  

  • 9. [Proposals for the legal control of the testing and introduction of drugs based on a comparison of drug laws in other countries].
    Burow W; Lüllmann H
    Schriftenr Geb Off Gesundheitswes; 1971; 31():1-64. PubMed ID: 5153578
    [No Abstract]   [Full Text] [Related]  

  • 10. Bacteriological purity--a consideration in the manufacture and packaging of pharmaceuticals.
    Brennan EC; Baker DE; Gasdia SD
    Am J Hosp Pharm; 1968 Jun; 25(6):302-4. PubMed ID: 4968569
    [No Abstract]   [Full Text] [Related]  

  • 11. Formulation for optimal safety and effectiveness.
    Schlichting DA
    Am J Pharm Sci Support Public Health; 1970; 142(1):16-22. PubMed ID: 5535904
    [No Abstract]   [Full Text] [Related]  

  • 12. Sterile Product Packaging and Delivery Systems.
    Akers MJ
    Int J Pharm Compd; 2015; 19(6):491-500. PubMed ID: 26891564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Settling and impaction of particles into containers in manufacturing pharmacies.
    Whyte W
    J Parenter Sci Technol; 1981; 35(5):255-61. PubMed ID: 7299604
    [No Abstract]   [Full Text] [Related]  

  • 14. Stability issues of parenteral chemotherapy drugs.
    de Lemos ML; Hamata L
    J Oncol Pharm Pract; 2007 Mar; 13(1):27-31. PubMed ID: 17621564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Errors discovered in a manufacturing program.
    Das Gupta V
    Am J Hosp Pharm; 1973 Feb; 30(2):112. PubMed ID: 4690464
    [No Abstract]   [Full Text] [Related]  

  • 16. A product standards form for new radipharmaceuticals.
    Warbick A
    Am J Hosp Pharm; 1974 Feb; 31(2):165-6. PubMed ID: 4815850
    [No Abstract]   [Full Text] [Related]  

  • 17. Human and veterinary drugs: good manufacturing practices and proposed exemptions for certain OTC products.
    Fed Regist; 1978 Sep; 43(190 Pt 2):45013-89. PubMed ID: 10316700
    [No Abstract]   [Full Text] [Related]  

  • 18. [Drug incompatibilities. Problems in the simultaneous administration of drugs in infusions].
    Kähny-Simonius J
    Schweiz Rundsch Med Prax; 1993 Nov; 82(46):1320-7. PubMed ID: 8265949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current good manufacturing practice regulations.
    Bumiller J
    Bull Parenter Drug Assoc; 1971; 25(5):222-5. PubMed ID: 5094094
    [No Abstract]   [Full Text] [Related]  

  • 20. Spurious and counterfeit drugs: a growing industry in the developing world.
    Gautam CS; Utreja A; Singal GL
    Postgrad Med J; 2009 May; 85(1003):251-6. PubMed ID: 19520877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.